Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis.

@article{Montagna2013BenefitOD,
  title={Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis.},
  author={Giovanni Montagna and Benedetta Cazzulani and Laura Obici and Carla Uggetti and Sofia Giorgetti and Riccardo Porcari and Rubina Ruggiero and Palma Patrizia Mangione and M. Brambilla and Jacopo Lucchetti and Giovanna Guiso and Marco Gobbi and Giampaolo Merlini and Mario Salmona and Monica Stoppini and Giuseppe Villa and Vittorio Bellotti},
  journal={Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis},
  year={2013},
  volume={20 3},
  pages={173-8}
}
Abstract Doxycycline inhibits amyloid formation in vitro and its therapeutic efficacy is under evaluation in clinical trials for different protein conformational diseases, including prion diseases, Alzheimer's disease and transthyretin amyloidosis. In patients on chronic hemodialysis, a persistently high concentration of β2-microglobulin causes a form of amyloidosis (dialysis-related amyloidosis, DRA) localized in bones and ligaments. Since doxycycline inhibits β2-microglobulin fibrillogenesis… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS